



A Short Route to "Reverse-Prenylated" Pyrrolo[2,3-*b*]indoles via Tandem Olefination and Claisen Rearrangement of 2-(3,3- Dimethylallyloxy)indol-3-ones: First Total Synthesis of Flustramine C


Tomomi Kawasaki, Romi Terashima, Ken-ei Sakaguchi,
Hiroko Sekiguchi, and Masanori Sakamoto*

Meiji College of Pharmacy, 1-35-23 Nozawa, Setagaya-ku, Tokyo 154, Japan

Abstract: The Wittig or Horner-Emmons reaction of 1-acetyl-2-(3,3-dimethylallyloxy)indol-3-ones proceeded via tandem olefination, isomerization, Claisen rearrangement, and deacetylation to give 3-cyanomethyl-3-(1,1-dimethylallyl)indol-2-ones in good yields, which were reduced with Red-Al[®] to afford pyrrolo[2,3-*b*]indoles having the 1,1-dimethylallyl group at the 3a-position. The first total synthesis of the marine alkaloid flustramine C was also described.


Copyright © 1996 Elsevier Science Ltd

The pyrrolo[2,3-*b*]indole ring system possessing the 1,1-dimethylallyl ("reverse-prenyl") group at the 3a-site represents a key structural subunit in a number of biological important natural products such as ardeemin (1),¹ 5-*N*-acetylardeemin (2),¹ amaumomine (3),² aszonalenin (4),³ and flustramine C (5).⁴ Three routes to 3a-(1,1-dimethylallyl)pyrrolo[2,3-*b*]indole nucleus were reported, via alkylation of tryptamine with 1,1-dimethylpropargyl chloride,⁵ thio-Claisen rearrangement,⁶ and direct substitution of 3a-phenylselenopyrrolo[2,3-*b*]indole with prenyl tributylstannane.⁷ Our interest in developing a general synthetic strategy to these and other related compounds necessitated the introduction of 1,1-dimethylallyl group to the corresponding 3a-position of pyrrolo[2,3-*b*]indole structure. Recently, we have shown the Wittig reaction of indolin-3-ones as a useful method for preparing 3-substituted indoles,⁸ and the Claisen rearrangement of 2-(3,3-dimethylallyloxy)indoles as a manner for introducing 1,1-dimethylallyl moiety at the 2-site of the indole nucleus.⁹ In this paper we describe an efficient method for synthesis of 3a-(1,1-di-



methylallyl)pyrrolo[2,3-*b*]indole *via* tandem olefination, isomerization, and Claisen rearrangement of 2-(3,3-dimethylallyloxy)indolin-3-one (**8**) to 3-substituted 3-(1,1-dimethylallyl)indol-2-ones (**13**). We have applied this methodology to the first total synthesis of the marine alkaloid flustramine C (**5**).


The starting 2-(3,3-dimethylallyloxy)indolin-3-one (**8**)¹⁰ was obtained in 73% overall yield by the bromination¹¹ of readily available indolin-3-one (**6**)¹² followed by substitution with prenyl alcohol (**7**) in the presence of molecular sieves (MS) 4A. The Wittig reaction of **8** with cyanomethylidene-triphenylphosphorane (**9a**) in refluxing toluene for 5 h gave a mixture (*E* : *Z* = 1 : 3) of *E*- and *Z*-isomers of the 3-alkylideneindoline (**11a**) in 70% yield. Prolonged heating of **11a** under the same conditions failed to isomerize to an indole (**12a**). When **11a** was treated with 1,8-diazabicyclo-[5.4.0]undec-7-ene (DBU) at room temperature, it underwent smoothly successive isomerization and Claisen rearrangement affording indolin-2-ones (**13a**, 13%) and (**14a**, 47%),¹³ which have the reversed prenyl group at the desired position. The 'one pot' procedure of these reactions achieved the synthetic purpose, namely the reaction of **8** with **9a** followed by treatment of the resulting mixture with DBU provided **13a** (14%) and **14a** (72%). Similarly, the 'one pot' reaction of **8** with **9b** gave the corresponding products, **13b** (39%) and **14b** (35%). When the reaction of **8** was performed using cyanomethylphosphonate (**10**) with potassium *tert*-butoxide instead of the ylides (**9**), the tandem olefination, isomerization, Claisen rearrangement, and deacetylation proceeded more smoothly at -60 °C and then at room temperature for 5 h to afford **14a** in quantitative overall yield.



Scheme 1

Transformation of the indolin-2-one **14a** to pyrrolo[2,3-*b*]indole (**15**) was achieved by reductive cyclization of **14a** using Red-Al^{®14} to give **15** in 73% yield. The present methodology is useful for the synthesis of 3a-(1,1-dimethylallyl)pyrrolo[2,3-*b*]indole derivatives, and we next applied this method to synthesis of flustramine C (**5**).

6-Bromoindolin-3-one (**18**) was readily prepared from 6-bromoindole (**16**)¹⁵ by N-acetylation followed by molybdenum peroxide oxidation¹⁶ and demethoxylation¹² of the oxidation product (**17**) with tin (IV) chloride in 43% overall yield. Bromination of **18** followed by substitution with prenyl alcohol (**7**) gave the ether (**19**) in 89% yield. The tandem reaction of **19** to the indolin-2-one (**20**) (73%) was then accomplished by treatment with the phosphonate (**10**). Reduction of **20** with Red-Al[®] afforded the pyrrolo[2,3-*b*]indole (**21**) (89%), which was alkylated using methyl iodide in the presence of sodium bicarbonate to give flustramine C (**5**)⁴, **17** (38%) together with its isomer (**22**) (29%).



Scheme 2. Reagents and Conditions : i, AcCl, 33 % NaOH, Bu₄NHSO₄; ii, MoO₃·HMPA, MeOH; iii, SnCl₄; iv, Br₂; v, Me₂C=CHCH₂OH **7**, MS 4A; vi, (EtO)₂P(O)CH₂CN **10**, *t*-BuOK; vii, Red-Al; viii, MeI, NaHCO₃

In summary, we have demonstrated the first total synthesis of flustramine C using the tandem olefination, isomerization, Claisen rearrangement, and deacetylation of 2-(3,3-dimethylallyloxy)indolin-3-ones. This tandem reaction is a useful strategy for constructing pyrrolo[2,3-*b*]indole alkaloids involving the "reverse-prenyl" group at 3a-position.

ACKNOWLEDGEMENT: We wish to thank Professor C. Christophersen (University of Copenhagen, Denmark) for providing spectral data of natural flustramine C. This research program was supported by Special Coordination Funds of the Science and Technology Agency of the Japanese Government.

REFERENCES AND NOTES

- Karwowski, J. P.; Jackson, M.; Rasmussen, R. R.; Humphrey, P. E.; Poddig, J. B.; Kohl, W. L.; Scherr, M. H.; Kadam, S.; McAlpine, J. B. *J. Antibiot.* **1993**, *46*, 374-379. Hochlowski, J. P.; Mullally, M. M.; Spanton, S. G.; Whittern, D. N.; Hill, P.; McAlpine, J. B. *J. Antibiot.* **1993**, *46*, 380-386.
- Takase, S.; Iwami, M.; Ando, T.; Okamoto, M.; Yoshida, K.; Horiai, H.; Kohsaka, M.; Aoki, H.; Imanaka, H. *J. Antibiot.* **1984**, *37*, 1320-1323. Takase, S.; Kawai, Y.; Uchida, I.; Tanaka, H.; Aoki, H. *Tetrahedron* **1985**, *41*, 3037-3048.
- Kimura, Y.; Hamasaka, T.; Nakajima, H.; Isogai, A. *Tetrahedron Lett.* **1982**, *23*, 225-228.

4. Carlé, J. S.; Christophersen, C. *J. Org. Chem.* **1981**, *46*, 3440-3443.
5. Takase, S.; Itoh, Y.; Uchida, I.; Tanaka, H.; Aoki, H. *Tetrahedron Lett.* **1985**, *26*, 847-850. Bhat, B.; Harrison, D. M. *Tetrahedron Lett.* **1986**, *27*, 5873-5874. Takase, S.; Uchida, I.; Tanaka, H.; Aoki, H. *Tetrahedron* **1986**, *42*, 5879-5886. Takase, S.; Itoh, Y.; Uchida, I.; Tanaka, H.; Aoki, H. *Tetrahedron* **1986**, *42*, 5887-5894. Bhat, B.; Harrison, D. M. *Tetrahedron* **1993**, *49*, 10655-10662. Bhat, B.; Harrison, D. M.; Lamont, H. M. *Tetrahedron* **1993**, *49*, 10663-10668.
6. Hino, T.; Hasumi, K.; Yamaguchi, H.; Taniguchi, M.; Nakagawa, M. *Chem. Pharm. Bull.* **1985**, *33*, 5202-5206.
7. Marsden, S. P.; Depew, K. M.; Danishefsky, S. J. *J. Am. Chem. Soc.* **1994**, *116*, 11143-11144.
8. Kawasaki, T.; Watanabe, K.; Masuda, K.; Sakamoto, M. *J. Chem. Soc., Chem. Commun.* **1995**, 381-382.
9. Kawasaki, T.; Nonaka, Y.; Ohtsuka, H.; Sato, H.; Sakamoto, M. *J. Chem. Soc., Perkin Trans. I* **1990**, 1101-1106. Kawasaki, T.; Nonaka, Y.; Uemura, M.; Sakamoto, M. *Synthesis* **1991**, 701-702. Kawasaki, T.; Nonaka, Y.; Akahane, M.; Maeda, N.; Sakamoto, M. *J. Chem. Soc., Perkin Trans. I* **1993**, 1777-1781. Kawasaki, T.; Masuda, K.; Baba, Y.; Takada, K.; Sakamoto, M. *Chem. Pharm. Bull.* **1994**, *42*, 1974-1976. Kawasaki, T.; Masuda, K.; Baba, Y.; Terashima, R.; Takada, K.; Sakamoto, M. *J. Chem. Soc., Perkin Trans. I* **1996**, 729-733.
10. All new compounds were characterized by $^1\text{H-NMR}$, IR, and MS data and gave satisfactory analytical and/or high resolution MS data.
11. Velezheva, V. S.; Mel'man, A. I.; Smushkevich, Y. I.; Pol'shakov, V. I.; Anisimova, O. S. *Khim.-Farm. Zh. SSSR* **1990**, *24*, 46-51 (*Chem. Abstr.* **1991**, *114*, 228786u).
12. Chien, C.-S.; Hasegawa, A.; Kawasaki, T.; Sakamoto, M. *Chem. Pharm. Bull.* **1986**, *34*, 1493-1496.
13. Compound (**14a**) mp: 154-155 °C; IR (CHCl_3): ν 3434, 2255, 1716 cm^{-1} ; $^1\text{H-NMR}$ (270 MHz, CDCl_3): δ 1.08 (3H, s), 1.16 (3H, s), 2.86 (1H, d, $J = 14.5$ Hz), 3.01 (1H, d, $J = 14.5$ Hz), 5.99 (1H, d, $J = 17.5$ Hz), 5.22 (1H, d, $J = 10.9$ Hz), 6.08 (1H, dd, $J = 17.5, 10.9$ Hz), 6.92 (1H, d, $J = 7.6$ Hz), 7.07 (1H, t, $J = 7.6$ Hz), 7.27 (1H, d, $J = 7.6$ Hz), 7.29 (1H, t, $J = 7.6$ Hz), 8.12 (1H, br s); HRMS calcd for $\text{C}_{15}\text{H}_{16}\text{N}_2\text{O}$ [M^+] 240.1263, found 240.1263.
14. Pei, X.-F.; Bi, S. *Heterocycles* **1994**, *39*, 357-360.
15. Dellar, G.; Djura, P.; Sargent, M. V. *J. Chem. Soc., Perkin Trans. I* **1981**, 1679-1680.
16. Chien, C.-S.; Suzuki, T.; Kawasaki, T.; Sakamoto, M. *Chem. Pharm. Bull.* **1984**, *32*, 3945-3951.
17. Flustramine C (**5**); IR (CHCl_3): ν 1636, 1586, 1565 cm^{-1} ; $^1\text{H-NMR}$ (270 MHz, CDCl_3): δ 0.89 (3H, s), 0.99 (3H, s), 2.06 (1H, ddd, $J = 8.9, 9.9, 12.9$ Hz), 2.35 (1H, dd, $J = 6.6, 12.9$ Hz), 3.02 (3H, s), 3.39 (1H, t, $J = 9.9$ Hz), 3.94 (1H, ddd, $J = 6.6, 8.9, 9.9$ Hz), 5.04 (1H, d, $J = 17.2$ Hz), 5.06 (1H, d, $J = 10.9$ Hz), 6.01 (1H, dd, $J = 10.9, 17.2$ Hz), 6.906 (1H, d, $J = 7.9$ Hz), 6.908 (1H, d, $J = 7.9$ Hz), 7.20 (1H, t, $J = 1.0$ Hz); $^{13}\text{C-NMR}$ (67.8 MHz, CDCl_3): δ 21.6, 22.8, 27.9, 33.2, 42.9, 59.7, 65.7, 113.6, 119.1, 121.9, 122.0, 124.3, 137.6, 143.4, 163.5, 188.1; MS m/z 320 ($\text{M}+2$, 32%), 318 (M^+ , 33), 251 (99), 249 (100), 210 (4), 208 (5), 170 (42), 129 (13), 69 (5); HRMS calcd for $\text{C}_{16}\text{H}_{19}\text{BrN}_2$ [M^+] 318.0732, found 318.0730.

(Received in Japan 24 July 1996; revised 22 August 1996; accepted 26 August 1996)